IL309037A - Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors - Google Patents
Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitorsInfo
- Publication number
- IL309037A IL309037A IL309037A IL30903723A IL309037A IL 309037 A IL309037 A IL 309037A IL 309037 A IL309037 A IL 309037A IL 30903723 A IL30903723 A IL 30903723A IL 309037 A IL309037 A IL 309037A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- compound
- tumor
- lymphoma
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196744P | 2021-06-04 | 2021-06-04 | |
| PCT/US2022/032203 WO2022256680A1 (en) | 2021-06-04 | 2022-06-03 | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309037A true IL309037A (en) | 2024-02-01 |
Family
ID=82321319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309037A IL309037A (en) | 2021-06-04 | 2022-06-03 | Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240254123A1 (enExample) |
| EP (1) | EP4347592A1 (enExample) |
| JP (1) | JP2024522304A (enExample) |
| KR (1) | KR102997319B1 (enExample) |
| CN (1) | CN117794932A (enExample) |
| AU (2) | AU2022287033B2 (enExample) |
| CA (1) | CA3225152A1 (enExample) |
| IL (1) | IL309037A (enExample) |
| MX (1) | MX2023014466A (enExample) |
| WO (1) | WO2022256680A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240158972A (ko) | 2022-03-07 | 2024-11-05 | 데비오팜 인터네셔날 에스 에이 | 소세포 폐암의 치료 방법 |
| EP4777102A1 (en) | 2023-09-14 | 2026-07-22 | Debiopharm International SA | Combination of a wee1 inhibitor and a pkmyt1 inhibitor |
| CN120189510A (zh) * | 2023-12-21 | 2025-06-24 | 北京哲源科技有限责任公司 | 一种并环化合物的应用 |
| TW202541810A (zh) | 2023-12-22 | 2025-11-01 | 瑞士商德彪製藥國際公司 | 治療實體腫瘤之方法 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201612095D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| GB201800378D0 (en) * | 2018-01-10 | 2018-02-21 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2022
- 2022-06-03 US US18/565,598 patent/US20240254123A1/en active Pending
- 2022-06-03 JP JP2024518956A patent/JP2024522304A/ja active Pending
- 2022-06-03 WO PCT/US2022/032203 patent/WO2022256680A1/en not_active Ceased
- 2022-06-03 CN CN202280054331.6A patent/CN117794932A/zh active Pending
- 2022-06-03 MX MX2023014466A patent/MX2023014466A/es unknown
- 2022-06-03 AU AU2022287033A patent/AU2022287033B2/en active Active
- 2022-06-03 EP EP22735735.7A patent/EP4347592A1/en active Pending
- 2022-06-03 CA CA3225152A patent/CA3225152A1/en active Pending
- 2022-06-03 KR KR1020247000364A patent/KR102997319B1/ko active Active
- 2022-06-03 IL IL309037A patent/IL309037A/en unknown
-
2025
- 2025-06-23 AU AU2025204724A patent/AU2025204724A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022287033B2 (en) | 2025-04-17 |
| AU2022287033A1 (en) | 2024-01-18 |
| WO2022256680A1 (en) | 2022-12-08 |
| MX2023014466A (es) | 2024-05-02 |
| KR102997319B1 (ko) | 2026-07-30 |
| EP4347592A1 (en) | 2024-04-10 |
| US20240254123A1 (en) | 2024-08-01 |
| AU2025204724A1 (en) | 2025-07-10 |
| CA3225152A1 (en) | 2022-12-08 |
| KR20240044409A (ko) | 2024-04-04 |
| CN117794932A (zh) | 2024-03-29 |
| JP2024522304A (ja) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522304A5 (enExample) | ||
| JP7846086B2 (ja) | Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法 | |
| ES2537352T3 (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| CN106860870B (zh) | 抗肿瘤生物碱的联合治疗 | |
| CN110913861B (zh) | G1t38的形态学形式及其制造方法 | |
| JP2014533699A5 (enExample) | ||
| ES2822654T3 (es) | Benzimidazol-2-aminas como inhibidores de mIDH1 | |
| JP2017517548A5 (enExample) | ||
| EA035658B1 (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| JP2008509948A (ja) | 細胞増殖を伴う疾患の治療のための複合薬 | |
| JP2020510032A5 (enExample) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| JP2022507025A5 (enExample) | ||
| JP2018534289A5 (enExample) | ||
| RU2010133979A (ru) | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов | |
| ES3032458T3 (en) | Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | |
| RU2014142057A (ru) | Комплексная терапия | |
| JP2019526560A5 (enExample) | ||
| CN118986981A (zh) | 用于治疗或预防癌症的喹啉衍生物 | |
| CN106459011B (zh) | 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 | |
| EP4134098A1 (en) | Method of cancer therapy | |
| EP3973963A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| EP3310746A1 (en) | New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol | |
| CN116057051A (zh) | 白介素-1受体相关激酶1和4的抑制剂 |